Anhui, China

Fengchao Lv

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Tarapeutics Science Inc.. Active years: 2020.


% Patents Active = 100.0

 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Fengchao Lv

Introduction

Fengchao Lv is a notable inventor based in Anhui, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work primarily focuses on the inhibition of histone methyltransferase EZH2, which plays a crucial role in various cancerous conditions.

Latest Patents

Fengchao Lv holds a patent for an EZH2 inhibitor and its use. This patent describes an inhibitor of both the wild type and Y641F mutant of human histone methyltransferase EZH2. The compound, represented by formula (I) or a pharmaceutically acceptable salt thereof, is designed to treat cancers or precancerous conditions associated with EZH2 activity. He has 1 patent to his name.

Career Highlights

Fengchao Lv is currently associated with Therapeutics Science Inc., where he continues to advance his research in cancer therapies. His work has garnered attention for its potential impact on treatment options for patients suffering from various forms of cancer.

Collaborations

Fengchao has collaborated with notable colleagues, including Qingsong Liu and Jing Liu, to further enhance the scope and effectiveness of his research. Their combined expertise contributes to the innovative approaches being developed at Therapeutics Science Inc.

Conclusion

Fengchao Lv's contributions to the field of cancer treatment through his innovative EZH2 inhibitor highlight the importance of research and collaboration in advancing medical science. His work continues to pave the way for new therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…